Recommended Conferences

Genetic Engineering and Gene Therapy

Paris, France

Human Genetics and Genetic Disorders

Miami, USA

Tissue Engineering and Regenerative Medicine

Chicago, USA
Related Subjects

Gene expression profiling and pathway analysis of superficial bladder cancer in rats

Author(s): Arum CJ,Anderssen E, Tømmerås K, Lundgren S, Chen D, et al.


Objectives: To reveal the gene expression profile and pathways involved in host-tumor interactions in a rat orthotopic syngeneic bladder cancer model.

Methods: Rat bladder cancer cells (AY-27 cell line) were inoculated intravesically into female Fischer rats. The bladders were analyzed at 7, 14, and 28 days by histologic examination and at 14 days with Affymetrix GeneChip with a newly developed bioinformatics program for the Kyoto Encyclopedia of Genes and Genomes (KEGG).

Results: The cancer had developed into Stage Ta and carcinoma in situ (Tis) after 7 days, Stage T1 after 14 days, and Stage T3 after 28 days in the bladder. At 14 days, >4000 genes were found to be differentially expressed and 20 KEGG pathways were actively involved in the bladder. The molecular pathway for (human) bladder cancer development was activated, and, at the same time, pathways in connection with the host immune responses were altered, including antigen processing and presentation, the T-cell receptor signaling pathway, natural killer cell-mediated cytotoxicity, the Toll-like receptor signaling pathway, and the B-cell receptor signaling pathway. Moreover, the cell adhesion molecules associated with the immune system were upregulated, but those associated with the neural system were downregulated.

Conclusions: The bladder cancer developed aggressively despite active host immune responses. Conceivably, the cancer immunoediting process is associated with the progression of bladder cancer in this model.

Similar Articles

Bladder cancer biomarkers: review and update

Author(s): Ghafouri-Fard S,Nekoohesh L, Motevaseli E

Recent advances in the diagnosis and treatment of bladder cancer

Author(s): Cheung G,Sahai A, Billia M, Dasgupta P, Khan MS

Primary bladder preservation treatment for urothelial bladder cancer

Author(s): Biagioli MC, Fernandez DC, Spiess PE, Wilder RB

Prediction of muscle-invasive bladder cancer using urinary proteomics

Author(s): Schiffer E,Vlahou A, Petrolekas A, Stravodimos K, Tauber R, et al.

Making sense of cancer genomic data

Author(s): Chin L, Hahn WC, Getz G, Meyerson M

Principles and methods of integrative genomic analyses in cancer

Author(s): Kristensen VN,Lingjærde OC,Russnes HG,Vollan HK,Frigessi A, et al.

affy--analysis of Affymetrix GeneChip data at the probe level

Author(s): Gautier L, Cope L, Bolstad BM, Irizarry RA

Biomarkers for bladder cancer aggressiveness

Author(s): Frantzi M,Makridakis M, Vlahou A

Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma

Author(s): De Giorgi V, Monaco A, Worchech A, Tornesello M, Izzo F, et al.

The double bromodomain protein Brd2 promotes B cell expansion and mitogenesis

Author(s): Belkina AC, Blanton WP, Nikolajczyk BS, Denis GV

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer

Author(s): Wyce A,Degenhardt Y, Bai Y, Le B, Korenchuk S, et al.

A UPF3-mediated regulatory switch that maintains RNA surveillance

Author(s): Chan WK,Bhalla AD, Le Hir H, Nguyen LS, Huang L, et al.

Targeted therapies in urothelial carcinoma

Author(s): Ghosh M,Brancato SJ, Agarwal PK, Apolo AB

Activation of RAS family genes in urothelial carcinoma

Author(s): Boulalas I,Zaravinos A, Karyotis I, Delakas D, Spandidos DA

Ras mutation cooperates with ß-catenin activation to drive bladder tumourigenesis

Author(s): Ahmad I, Patel R, Liu Y, Singh LB, Taketo MM, et al.

Ras in cancer and developmental diseases

Author(s): Fernández-Medarde A, Santos E